Scintimun
·
- Prescription status not stated
- Everything that fits nowhere else, such as contrast media
- Active substance
- Besilesomab
- Made by
- Telix Innovations
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- This medicinal product is for diagnostic use only and the approved indication is scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. Scintimun should not be used for the diagnosis of diabetic foot infection.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Telix Innovations |
|---|---|
| Active substance | Besilesomab |
| Used in | Everything that fits nowhere else, such as contrast media |
| Classification | V09HA03 · Everything that fits nowhere else, such as contrast media |
| Authorised on | 2010-01-11 |
| Last updated by the regulator | 2026-06-09 |
| EMA product number | EMEA/H/C/001045 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).